Finerenone plus empagliflozin vs each alone in CKD with type 2 diabetes

Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) comparing Finerenone + empagliflozin, Finerenone alone and Empagliflozin alone (3 arms). Primary endpoints: Mean ratio of change from baseline to Day 180 in urinary albumin-to-creatinine ratio (UACR): combination vs empagliflozin alone and Mean ratio of change from baseline to Day 180 in urinary albumin-to-creatinine ratio (UACR): combination vs finerenone alone. Started May 2024; status: completed.